secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0000950170-24-126342
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna Q3 net loss $34.3M; CMO James Chung resigns effective Nov 22
--------------------------------------------------------------------

- Net loss of $34.3M ($0.80 per share) vs. $15.5M loss in prior-year quarter.
- Cash, equivalents and marketable securities $321.6M as of Sep 30, 2024.
- CMO James Chung, M.D., Ph.D. resigns effective Nov 22; search for replacement underway.
- CEO Warner Biddle appointed; Board adds Christi Shaw and Mert Aktar.
- KYV-101 advances: Phase 2 dosing in myasthenia gravis; RMAT and Orphan Drug designations in multiple indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000095017024126342/0000950170-24-126342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000095017024126342/kytx-20241108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-126342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer